These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8492137)

  • 21. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease.
    Faucheux BA; Nillesse N; Damier P; Spik G; Mouatt-Prigent A; Pierce A; Leveugle B; Kubis N; Hauw JJ; Agid Y
    Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9603-7. PubMed ID: 7568181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models.
    Martínez-Mir MI; Pollard H; Moreau J; Traiffort E; Ruat M; Schwartz JC; Palacios JM
    Synapse; 1993 Nov; 15(3):209-20. PubMed ID: 7904088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?
    Mouatt-Prigent A; Agid Y; Hirsch EC
    Brain Res; 1994 Dec; 668(1-2):62-70. PubMed ID: 7704619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemistry of Parkinson's disease with special reference to the dopaminergic systems.
    Hirsch EC
    Mol Neurobiol; 1994; 9(1-3):135-42. PubMed ID: 7888089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease.
    Anichtchik OV; Peitsaro N; Rinne JO; Kalimo H; Panula P
    Neurobiol Dis; 2001 Aug; 8(4):707-16. PubMed ID: 11493035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization and distribution of [125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain.
    Joyce JN; Janowsky A; Neve KA
    J Pharmacol Exp Ther; 1991 Jun; 257(3):1253-63. PubMed ID: 1828505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron transport in Parkinson's disease.
    Hirsch EC
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S209-11. PubMed ID: 20082992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative susceptibility mapping of the midbrain in Parkinson's disease.
    Du G; Liu T; Lewis MM; Kong L; Wang Y; Connor J; Mailman RB; Huang X
    Mov Disord; 2016 Mar; 31(3):317-24. PubMed ID: 26362242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The distribution of excitatory amino acid receptors in the normal human midbrain and basal ganglia with implications for Parkinson's disease: a quantitative autoradiographic study using [3H]MK-801, [3H]glycine, [3H]CNQX and [3H]kainate.
    Ball EF; Shaw PJ; Ince PG; Johnson M
    Brain Res; 1994 Sep; 658(1-2):209-18. PubMed ID: 7834343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease.
    Faucheux BA; Martin ME; Beaumont C; Hunot S; Hauw JJ; Agid Y; Hirsch EC
    J Neurochem; 2002 Oct; 83(2):320-30. PubMed ID: 12423242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
    Damier P; Hirsch EC; Agid Y; Graybiel AM
    Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glutamate receptors in the substantia nigra of Parkinson's disease brains.
    Difazio MC; Hollingsworth Z; Young AB; Penney JB
    Neurology; 1992 Feb; 42(2):402-6. PubMed ID: 1346548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions.
    Loeffler DA; Connor JR; Juneau PL; Snyder BS; Kanaley L; DeMaggio AJ; Nguyen H; Brickman CM; LeWitt PA
    J Neurochem; 1995 Aug; 65(2):710-24. PubMed ID: 7616227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics and distribution of [59Fe-125I]transferrin injected into the ventricular system of the rat.
    Moos T; Morgan EH
    Brain Res; 1998 Apr; 790(1-2):115-28. PubMed ID: 9593852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease.
    McRitchie DA; Cartwright HR; Halliday GM
    Exp Neurol; 1997 Mar; 144(1):202-13. PubMed ID: 9126172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The transferrin receptor in hepatocyte nodules: binding properties, subcellular distribution and endocytosis.
    Eriksson LC; Torndal UB; Andersson GN
    Carcinogenesis; 1986 Sep; 7(9):1467-74. PubMed ID: 3017598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Akt signal transduction dysfunction in Parkinson's disease.
    Timmons S; Coakley MF; Moloney AM; O' Neill C
    Neurosci Lett; 2009 Dec; 467(1):30-5. PubMed ID: 19800394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of transferrin in heme transport.
    Stout DL
    Biochem Biophys Res Commun; 1992 Dec; 189(2):765-70. PubMed ID: 1472048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Photoaffinity labeling of neurotensin binding sites on rat brain sections.
    Rostène WH; Mazella J; Dussaillant M; Vincent JP
    Eur J Pharmacol; 1986 Nov; 130(3):337-40. PubMed ID: 3025005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.